Economics of Health Care Systems

Rachel Meacock reports on the economics of elevated hospital mortality at weekends.

A Seminar Briefing on the topic of improving the fiscal and political sustainability of health systems through integrated population needs-based planning has just been published by OHE.

The issue of health service planning regularly hits the headlines. In a speech delivered in October by the Chief Executive of NHS England, Simon Stevens described a “mismatch between resources and patient needs of nearly £30 billion a year by 2020/21”.

Towse, A.

Occasional Paper
December 2014

This OHE Occasional Paper by Adrian Towse discusses Professor Bengt Jönsson’s observations in a 2011 publication about the role of relative effectiveness research (RE) in the European medicines market and how this could lead to improved efficiency in the development of medicines, the pricing and use of medicines, and of health systems.

Series on Health
July 1964

The cost of the National Health Service in the United Kingdom now exceeds £l,000m. per year. Ten years ago, when expenditure was less than half this amount, the cost of the Health Service was the source of continued public concern. Cost was "the one aspect of the National Health Service which, since its inception in 1948, has given rise to more critical discussion and controversy than any other single issue". The controversy has now largely died away, and expenditure on the Service is no longer viewed with such alarm or disquiet.

McKenzie, J. ed.

July 1969

Proceedings of a Symposium held at The Royal College of General Practitioners, London
15 September 1968

Series on Health
July 1968

The total expenditure on medicines in the United Kingdom in 1966 was £267 million. Of this £188 million was for medicines prescribed on the National Health Service. The other £79 million was spent by the public mainly for medicines bought without a doctor's prescription. Thus self-treatment still forms an important aspect of medical care, although in terms of cost it accounts for less than half per cent of total consumer expenditure.

Barnsley, P., Towse, A., Karlsberg Schaffer, S. and Sussex, J

Occasional Paper
December 2013

This paper counters the recently-published recommendation by Claxton et al[1] that NICE should lower its cost-per-QALY threshold from the current £20,000–£30,000 official range to £12,936.

Towse, A., Garrison, L. and Puig-Peiro, R.

Occasional Paper
February 2012

Interest is growing in schemes that involve “paying for pills by results”, that is, “paying for performance” rather than merely “paying for pills”.  Despite its intuitive appeal, this approach is highly controversial and is disliked by many health care providers, policy makers, and pharmaceutical companies.


Subscribe to RSS - Economics of Health Care Systems